Stable Anti-ifnar1 formulation
Stable, low viscosity antibody formulations with specific components and pH ranges address stability issues, enhancing the shelf life and efficacy of anti-interferon alpha receptor 1 antibodies by reducing denaturation and particle formation.
Patent Information
- Application Number
- JP2024140769
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2015-08-19
- Filing Date
- 2024-08-22
- Publication Date
- 2024-11-15
AI Technical Summary
Existing antibody formulations face challenges in maintaining stability during transportation and storage, particularly due to denaturation, aggregation, and particle formation, which are exacerbated by high antibody concentrations and varying physical properties such as viscosity.
The development of stable, low viscosity antibody formulations containing high concentrations of anti-interferon alpha receptor 1 antibodies, utilizing components like anifrolumab, lysine or lysine salts, uncharged excipients, surfactants, and formulation buffers, with specific pH and concentration ranges to enhance stability and reduce particle formation.
The formulations maintain biological activity and reduce particle formation, ensuring stability over extended periods, even at high antibody concentrations, thereby improving the efficacy and shelf life of antibody preparations.
Smart Images

Figure 2024161043000014 
Figure 2024161043000015 
Figure 2024161043000016
Abstract
Description
[Technical field]
[0001] This application incorporates by reference a Sequence Listing entitled "IFNAR-350WO1_SL.txt", created on Aug. 18, 2016, and having a size of 2,490, which was submitted herewith via EFS-Web as a text field.
[0002] The present invention relates to a stable, low-viscosity antibody formulation comprising a high concentration of an antibody that specifically binds to interferon alpha receptor 1 (IFNAR1) or an antigen-binding fragment thereof. In an embodiment, the antibody formulation comprises anifrolumab or an antigen-binding fragment thereof.
[0003] In some embodiments, the invention relates to a stable antibody formulation comprising about 100 mg / mL to about 200 mg / mL of an antibody or fragment thereof that specifically binds to IFNAR1; about 25 mM to about 130 mM lysine or a lysine salt; an uncharged excipient; a surfactant; and a formulation buffer. In some embodiments, the invention is directed to containers, dosage forms, and kits. In some embodiments, the invention is directed to methods of making and using the stable antibody formulations. [Background technology]
[0004] Antibodies are used in the treatment of various diseases and conditions due to their target recognition specificity, which results in highly selective outcomes following systemic administration. For antibodies to remain effective, they must maintain their biological activity during production, purification, transportation, and storage. New production and purification techniques have been developed to provide large amounts of highly pure monoclonal antibodies to be produced. However, there remains the challenge of stabilizing these antibodies for transportation and storage, and there is an even greater challenge of providing the antibodies in a dosage form suitable for administration.
[0005] Denaturation, aggregation, contamination, and particle formation can be significant obstacles in the formulation and storage of antibodies. Due to the wide variety of antibodies, there is no universal formulation or condition suitable for the storage of all antibodies. The optimal formulation of an antibody is often antibody-specific. Furthermore, antibody formulations may need to be further tailored to a particular antibody depending on the antibody concentration and / or the desired physical properties, such as the viscosity of the antibody formulation. Antibody storage formulations are often an important part of the research and development process for commercial antibodies. Summary of the Invention [Problem to be solved by the invention]
[0006] Various methods have been proposed to overcome the difficulties associated with antibody stability. For example, in some cases, antibodies are frequently lyophilized and then reconstituted immediately before administration. However, reconstitution adds an additional step to the administration process and may introduce contaminants into the formulation. In addition, reconstituted antibodies may face problems of aggregation and particle formation. Therefore, there is a need to provide a stable antibody formulation that can overcome the difficulties associated with transportation and storage. [Means for solving the problem]
[0007] The present invention relates to a stable, low-viscosity antibody formulation comprising a high concentration of an anti-interferon alpha receptor 1 antibody or an antigen-binding fragment thereof. In some embodiments, the present invention generally relates to a stable antibody formulation comprising about 100 mg / mL to about 200 mg / mL of an antibody that specifically binds to IFNAR1 or a fragment thereof, about 25 mM to about 130 mM of lysine or a lysine salt, an uncharged excipient, a surfactant, and a formulation buffer.
[0008] In embodiments, the invention is directed to an antibody formulation comprising about 100 mg / mL to about 200 mg / mL anifrolumab or antigen-binding fragment thereof; about 40 mM to about 60 mM lysine HCl; about 100 mM to about 160 mM trehalose dihydrate; about 0.02% to about 0.1% polysorbate 80; and about 15 mM to about 35 mM histidine / histidine HCl, wherein the formulation has a pH of about 5.5 to 6.5.
[0009] In embodiments, the invention is directed to an antibody formulation comprising about 145 mg / mL to about 155 mg / mL anifrolumab or antigen-binding fragment thereof; about 45 mM to about 55 mM lysine HCl; about 120 mM to about 140 mM trehalose dihydrate; about 0.04% to about 0.08% polysorbate 80; and about 20 mM to about 30 mM histidine / histidine HCl, wherein the formulation has a pH of about 5.8 to about 6.1.
[0010] In some embodiments, the invention is directed to an antibody formulation comprising about 150 mg / mL anifrolumab or an antigen-binding fragment thereof; about 50 mM lysine HCl; about 130 mM trehalose dihydrate; about 0.05% polysorbate 80; and about 25 mM histidine / histidine HCl, wherein the formulation has a pH of about 5.9.
[0011] In some embodiments, the invention is directed to an antibody formulation comprising 150 mg / mL anifrolumab or an antigen-binding fragment thereof; 50 mM Lysine HCl; 130 mM Trehalose dihydrate; 0.05% Polysorbate 80; and 25 mM Histidine / Histidine HCl, wherein the formulation has a pH of about 5.9.
[0012] In an additional embodiment, the invention is directed to an antibody formulation comprising 150 mg / mL anifrolumab; 50 mM Lysine HCl; 130 mM Trehalose dihydrate; 0.05% Polysorbate 80; 25 mM Histidine / Histidine HCl, wherein the formulation has a pH of 5.9.
[0013] In some embodiments, the invention is directed to a pharmaceutical unit dosage form suitable for parenteral administration to human beings comprising any one of the antibody formulations described herein in a suitable container.
[0014] In some embodiments, the invention is directed to a kit comprising any of the antibody formulations described herein, a container as described herein, a unit dose form as described herein, or a pre-filled syringe as described herein.
[0015] In some embodiments, the invention is directed to a method of producing a stable antibody formulation, comprising purifying an antibody to about 100 mg / mL to about 200 mg / mL of an anti-IFNAR antibody or antigen-binding fragment thereof, and placing the isolated antibody into a stabilized formulation to form a stable antibody formulation, the resulting stable antibody formulation comprising about 100 mg / mL to about 200 mg / mL of antibody; about 25 mM to about 130 mM lysine or lysine salt; about 100 mM to about 150 mM uncharged excipient; about 0.02% to about 0.1% surfactant; and formulation buffer.
[0016] In some embodiments, the present invention is directed to a method of treating a type I IFN-mediated disease or disorder in a subject in need thereof, comprising administering a therapeutically effective amount of any one of the antibody formulations described herein.
[0017] For the purpose of illustrating the invention, there are shown in the drawings certain embodiments of the invention. However, the invention is not limited to the precise arrangements and instrumentalities of the embodiments shown in the drawings. [Brief description of the drawings]
[0018] [Figure 1] In a high throughput screening bead-based method, viscosity as a function of pH is shown.
[0019] [Diagram 2]A high-throughput screening bead-based method is used to show viscosity as a function of lysine HCl concentration.
[0020] [Diagram 3] 1 shows viscosity as a function of antibody (anifrolumab) concentration for formulations containing 25 mM histidine / histidine HCl, 25 mM lysine, 130 mM trehalose at pH 6.0 (circles); and 25 mM histidine / histidine HCl, 50 mM lysine, 130 mM trehalose at pH 6.0 (diamonds).
[0021] [Figure 4] Viscosity is shown as a function of antibody (anifrolumab) concentration for solutions containing 0 mM lysine (diamonds); 5 mM lysine (squares); 12.5 mM lysine (triangles); 25 mM lysine (crosses); and 50 mM lysine (asterisks).
[0022] [Diagram 5] 4 shows viscosity as a function of lysine HCl concentration for solutions containing 135 mg / mL anifrolumab (diamonds); 150 mg / mL anifrolumab (squares); and 180 mg / mL anifrolumab (triangles). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0023] definition Before describing the invention in detail, it is understood that the invention is not limited to specific compositions or process steps that may vary. It should be noted that in the usage of this specification and the appended claims, the singular forms "a", "an" and "the" include plural referents unless the context clearly dictates otherwise. The terms "a" (or "an") and "one or more" and "at least one" may be used interchangeably herein.
[0024] Furthermore, "and / or" as used herein should be considered as a specific disclosure of each of the two specified features or components, with or without the other. Thus, the term "and / or" as used herein in phrases such as "A and / or B" is intended to include "A and B", "A or B", "A" (single), and "B" (single). Similarly, when used in phrases such as "A, B, and / or C", the term "and / or" is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (single); B (single); and C (single).
[0025] Throughout this disclosure, all expressions of percentages, ratios, and the like are "by weight" unless otherwise specified. As used herein, "by weight" is synonymous with the term "by mass" and indicates that the ratios or percentages defined herein are based on weight, not on volume, thickness, or other measure.
[0026] The term "about" is used herein to mean approximately, in a range, roughly, or around. When the term "about" is used in connection with a numerical range, it modifies the range by extending the boundaries above and below the numerical values set forth. In general, the term "about" is used herein to modify numerical values above and below the stated value by a variance of 10%.
[0027] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention pertains.For example, Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and Oxford Dictionary Of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press provide those skilled in the art with a general dictionary of many of the terms used in this disclosure.
[0028] Units, prefixes, and symbols are shown in their International System of Units (SI) accepted format. Numerical ranges are inclusive of the numbers that define the range. Unless otherwise specified, amino acid sequences are written from left to right in the amino to carboxy direction. The headings provided herein do not limit the various aspects or embodiments of the invention that may be had by reference to the entire specification. Thus, the terms defined immediately below are more fully defined by reference to the entire specification.
[0029] Whenever an embodiment is described herein using the word "comprising," it is understood that otherwise similar embodiments described by "consisting of" and / or "consisting essentially of" are also provided.
[0030] Amino acids are referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, are referred to by their commonly accepted single-letter codes.
[0031] As used herein, the term "ejection force" is the pressure (in Newtons) required to force the antibody formulation through a needle.
[0032] As used herein, the term "autoimmune disease" refers to a disorder, condition, or pathology associated with the formation of autoantibodies that react with the patient's own cells and form antigen-antibody complexes. The term "autoimmune disease" includes conditions such as systemic lupus erythematosus, and disorders caused by specific external agents such as acute rheumatic fever. Examples of autoimmune disorders include, but are not limited to, autoimmune hemolytic anemia, autoimmune hepatitis, Berger's disease, chronic fatigue syndrome, Crohn's disease, dermatomyositis, fibromyalgia, Graves' disease, Hashimoto's thyroiditis, idiopathic thrombocytopenic purpura, lichen planus, multiple sclerosis, myasthenia gravis, psoriasis, rheumatic fever, rheumatoid arthritis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, type I diabetes, ulcerative colitis, and vitiligo. In certain embodiments, the autoimmune disease is systemic lupus erythematosus (SLE), scleroderma (SSe), myositis, or lupus nephritis.
[0033] The terms "interferon alpha receptor-1", "IFNARI" and "IFNAR" are used interchangeably and include variants, isoforms and species homologs of human IFNAR1, including analogs having at least one epitope in common with IFNARI. See, e.g., de Weerd et al., J.Bioi.Chern.282:20053-20057 (2007). Thus, in certain instances, a human antibody specific for human IFNAR1 cross-reacts with IFNARI from species other than human, or with other proteins structurally related to human IFNAR1 (e.g., human IFNAR1 homologs). In other cases, the antibody may be completely specific for human IFNARI and does not exhibit species cross-reactivity or other types of cross-reactivity. The complete cDNA sequence of human IFNAR1 has Genbank accession number NM 000629.
[0034] The term "type I interferon" or "type I IFN" as used herein refers to a member of the type I interferon molecule family that is a ligand for IFNAR1 (i.e., a member of the type I interferon molecule family that can bind to IFNAR1). Examples of type I interferon ligands are interferon alpha 1, 2a, 2b, 4, 5, 6, 7, S, 10, 14, 16, 17, 21, interferon beta, and interferon omega.
[0035] The term "type I IFN-mediated disease or disorder" refers to any type I IFN or IFNa-induced disease, disorder, or condition that exhibits a type I IFN pharmacodynamics ("PD") marker expression profile or gene signature (type I IFN GS). PD marker expression profiles and gene signatures are understood to be equivalents. These diseases, disorders, or conditions include those with an autoimmune component, such as systemic lupus erythematosus (SLE), scleroderma, lupus nephritis, o myosotis, etc. Type I IFN-mediated diseases or disorders can be treated by administration of small molecules or biological agents, e.g., antibodies or antigen-binding fragments thereof. When the therapeutic agent is a biological agent, it can be an antibody specific for any subtype of type I IFN or IFNα. For example, the antibody may be specific for any one of IFNα1, IFNα2, IFNα4, IFNα5, IFNα6, IFNα7, IFNα8, IFNα10, IFNα14, IFNα17, IFNα21, IFNβ, or IFNω. Alternatively, the antibody may be specific for any two, any three, any four, any five, any six, any seven, any eight, any nine, any ten, any eleven, any twelve type I IFN or IFNα subtypes. When an antibody is specific for more than one type I IFN subtype, the antibody may be specific for IFNα1, IFNα2, IFNα4, IFNα5, IFNα8, IFNα10, and IFNα21; or it may be specific for IFNα1, IFNα2, IFNα4, IFNα5, IFNα8, and IFNα10; or it may be specific for IFNα1, IFNα2, IFNα4, IFNα5, IFNα8, and IFNα21; or it may be specific for IFNα1, IFNα2, IFNα4, IFNα5, IFNα10, and IFNα21. The therapeutic agent that modulates IFNα activity may neutralize IFNα activity. Type I IFN-mediated diseases or disorders may also be treated with an antibody specific for a type I IFN receptor, such as IFNAR1. In some embodiments, the anti-IFNAR1 antibody may cross-react with IFNAR1 from species other than human.In other embodiments, the anti-IFNAR1 antibody may be specific only for IFNAR1 and does not exhibit species or other types of cross-reactivity. In some embodiments, the anti-IFNAR1 antibody exhibits reduced binding affinity to Fc ligands, has reduced or reduced effector function (ADCC and / or CDC), reduced or reduced binding to Fc ligands, or reduced or reduced toxicity compared to unmodified antibodies.
[0036] The term "MEDI-546" refers to the Fc-modified version of the anti-IFNAR9D4 antibody described in US Patent No. 7,662,381. The terms "MEDI-546" and "anifrolumab" are used interchangeably herein. The sequence of MEDI-546 is described in US Patent No. 2011-0059078. MEDI-546 contains a combination of three mutations, L234F, L235E, and P331S, introduced into the lower hinge and CH2 domain of human IgG1, which cause their reduced binding to human FcyRI (CD64), FcyRIIA (CD32A), FcyRIII (CD16), and C1q, with numbering according to the EU index described in Kabat. See, e.g., U.S. Patent Application Publication No. 2011 / 0059078 and Oganesyan et al. Acta Crystallographica D 64:700-704 (2008), the contents of which are incorporated by reference in their entireties. The VH and Vκ sequences of MEDI-546 are shown in Table 1. [Table 1]
[0037] The term "antibody or antigen-binding fragment thereof that modulates type I IFN activity" refers to an antibody in its broadest sense that can modulate type I IFN activity in a patient (see below). The term "modulation", as used herein, includes inhibition or suppression of type I IFN activity, and induction or enhancement of type I IFN activity. In certain embodiments, the type I IFN activity is IFNα activity. In some embodiments, suppression of type IFN GS is suppression of type I IFN activity. In some embodiments, the antibody or antigen-binding fragment thereof is monoclonal. In certain embodiments, the antibody or antigen-binding fragment thereof that modulates type I IFN activity specifically binds to a type I IFN receptor, such as IFNAR1. In some particular embodiments, the antibody or antigen-binding fragment thereof specifically binds to subunit 1 of IFNAR1.
[0038] The term "antibody" is used herein in its broadest sense and includes, for example, monoclonal, polyclonal, multivalent, multispecific, chimeric, and humanized antibodies. The term "antibody" includes whole antibodies. The term "antibody" also refers to a protein comprising at least two immunoglobulin heavy (H) chains and two immunoglobulin light (L) chains interconnected by disulfide bonds or antigen-binding portions thereof. Each heavy chain is composed of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region is composed of three domains, CHI, CH2, and CH3. Each light chain is composed of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region is composed of one domain, CL. The VH and VL regions can be further subdivided into hypervariable regions called complementarity determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs). Each VH and VL is composed of three CDRs and four FRs arranged from amino terminus to carboxy terminus in the following order: FR1, CDRI, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of the antibody can mediate the binding of immunoglobulins to host tissues or elements, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.
[0039] The term "antigen-binding fragment" refers to one or more fragments of an antibody that retains the ability to specifically bind to an antigen (e.g., IFNAR). It has been shown that the antigen-binding function of an antibody can be performed by a fragment of a full-length antibody. Examples of binding fragments encompassed by the term "antigen-binding fragment" of an antibody include: (i) a Fab fragment, which is a monovalent fragment consisting of VL, VH, CL, and CHI domains; (ii) a F(ab')2 fragment, which is a bivalent fragment that contains two Fab fragments linked by a disulfide bridge in the hinge region; (iii) an Fd fragment consisting of VH and CHI domains; (iv) an Fv fragment consisting of the VL and VH domains of a single arm of an antibody; (v) a dAb fragment consisting of the VH domain (Ward et al., (1989) Nature 34I:544-546); and (vi) an isolated complementarity-determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are encoded by separate genes, they can be linked by a synthetic linker using recombinant techniques, in which the VL and VH regions pair into a single protein chain, forming a monovalent molecule known as a single chain Fv (scFv).See, for example, Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883).Such single chain antibodies are also intended to be encompassed by the term "antigen-binding fragment" of an antibody.These antibody fragments are obtained using conventional techniques known to those skilled in the art, and the fragments are screened for utility in the same manner as intact antibodies.
[0040] An "isolated antibody," as used herein, is intended to refer to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds to IFNAR is substantially free of antibodies that specifically bind to antigens other than IFNAR). However, an isolated antibody that specifically binds to IFNAR may have cross-reactivity with other antigens, such as IFNAR molecules from other species. Furthermore, an isolated antibody may be substantially free of other cellular material and / or chemicals.
[0041] The term "monoclonal antibody" as used herein refers to a preparation of antibody molecules of single molecular composition. A monoclonal antibody displays a single binding specificity and affinity for a particular epitope.
[0042] The term "human antibody", as used herein, is intended to include antibodies having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, the constant region is also derived from human germline immunoglobulin sequences. The human antibodies of the present disclosure may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, the term "human antibody", as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
[0043] The term "human monoclonal antibody" refers to an antibody exhibiting a single binding specificity having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. In one embodiment, a human monoclonal antibody is produced by a hybridoma comprising B cells obtained from a genetically modified non-human animal, such as a transgenic mouse, whose genome comprises human heavy and light chain transgenes fused to an immortalized cell.
[0044] The term "recombinant human antibody", as used herein, includes all human antibodies prepared, expressed, produced, or isolated by recombinant means, such as (a) antibodies isolated from animals (e.g., mice) that have been genetically engineered or transchromosomal with human immunoglobulin genes or hybridomas prepared therefrom (described in more detail below), (b) antibodies isolated from host cells transformed to express human antibodies, e.g., from transfectomas, (c) antibodies isolated from recombinant combinatorial human antibody libraries, and (d) antibodies prepared, expressed, produced, or isolated by any other means involving splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable regions in which the framework and CDR regions are derived from human germline immunoglobulin sequences. However, in certain embodiments, such recombinant human antibodies may be subject to in vitro mutagenesis (or in vivo somatic mutagenesis, when animals genetically modified for human Ig sequences are used) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies, while being sequences derived from and related to human germline VH and VL sequences, may not naturally occur within the human antibody germline repertoire in vivo.
[0045] The term "antibody", as used herein, also includes "chimeric" antibodies and fragments of such antibodies in which a portion of the heavy and / or light chains are identical to or homologous to corresponding sequences in antibodies from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chains are identical to or homologous to corresponding sequences in antibodies from another species or belonging to another antibody class or subclass, so long as they exhibit the desired biological activity (U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984)).
[0046] Basic antibody structure in vertebrate systems is relatively well known, see, e.g., Harlow et al. (1988) Antibodies: A Laboratory Manual (2nd ed.; Cold Spring Harbor Laboratory Press).
[0047] Where a term has more than one definition used and / or accepted in the art, the definition of the term used herein is intended to include all such meanings unless expressly stated otherwise. A particular example is the use of the term "complementarity determining region" ("CDR") to describe the non-adjacent antigen binding sites found in the variable regions of both heavy and light chain polypeptides. This particular region is described by Kabat et al. (1983) US Dept. of Health and Human Services, "Sequences of Proteins of Immunological Interest" and Chothia and Lesk, J. Mol. Bioi. 196:901-917 (1987), and the definitions include overlapping or subsets of amino acid residues when compared to each other. Nevertheless, it is intended to be within the scope of the term as defined and used herein to apply either definition to refer to the CDR of an antibody or variants thereof. The appropriate amino acid residues encompassing the CDRs as defined by each of the references cited above are set forth below in Table 2 for comparison. The exact residue numbers which encompass a particular CDR will vary depending on the sequence and size of the CDR. One skilled in the art can routinely determine the residues which encompass a particular CDR, given the variable region amino acid sequence of an antibody. [Table 2]
[0048] Kabat et al. also defined a numbering system for variable domain sequences that is applicable to any antibody. One of skill in the art can unambiguously assign this "Kabat numbering" system to any variable domain sequence without relying on any experimental data beyond the sequence itself. As used herein, "Kabat numbering" refers to the numbering system described in Kabat et al. (1983) US Dept. of Health and Human Services, "Sequence of Proteins of Immunological Interest". Unless otherwise specified, references to the numbering of specific amino acid residue positions in an anti-IFNAR antibody or antigen-binding fragment, variant, or derivative thereof of the present disclosure follow the Kabat numbering system.
[0049] The term "treat" or "treatment" as used herein refers to both therapeutic treatment and prophylactic or preventative measures, the purpose being to prevent or delay (alleviate) unwanted physiological changes or disorders in a subject, such as the progression of an inflammatory disease or condition. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, reduction in the extent of disease, stabilization of the disease state (i.e., no worsening), delay or slowing of disease progression, improvement or mitigation of the disease state, and remission (whether partial or complete) or non-detectability. The term "treatment" also means prolonging survival compared to the expected survival in the absence of treatment. Subjects in need of treatment include those already with a condition or disorder, and those susceptible to having a condition or disorder or those in whom a condition or disorder is to be prevented.
[0050] The terms "treating" or "treatment" or "treat" and the like refer to both (1) therapeutic measures that cure, delay, alleviate symptoms, and / or halt the progression of a diagnosed pathological condition or disorder, and (2) prophylactic or preventative measures that prevent and / or slow the progression of a targeted pathological condition or disorder. Thus, subjects in need of treatment include those already with the disorder; those susceptible to developing the disorder; and those in whom the disorder is to be prevented.
[0051] The terms "effective amount" or "amount effective for" or "therapeutically effective amount" include reference to a dosage of a therapeutic agent sufficient to produce a desired result.
[0052] "Subject" or "patient" refers to any subject, particularly a mammalian subject, for whom diagnosis, prognosis, or therapy is desired. As used herein, the term "subject" or "patient" includes any human or non-human animal. The term "non-human animal" includes all vertebrates, such as mammals and non-mammals, for example, non-human primates, sheep, dogs, cats, horses, cows, bears, chickens, amphibians, reptiles, etc. As used herein, phrases such as "patients with type I IFN-mediated diseases or disorders" include subjects, such as mammalian subjects, who will benefit from administration of an antibody or antigen-binding fragment thereof that modulates type I IFN activity, for example for detection, imaging, or other diagnostic procedures, and / or from treatment with such an antibody or antigen-binding fragment thereof, i.e., palliative or prevention of disease.
[0053] Antibody preparations In an embodiment, the present invention provides a stable antibody formulation comprising an anti-IFNAR1 antibody or an antigen-binding fragment thereof. In an embodiment, the anti-IFNAR1 antibody is anifrolumab. In an embodiment, the formulation of the present invention comprises both anifrolumab and its antigen-binding fragment.
[0054] In embodiments, the antibody formulations of the invention comprise an antibody or antigen-binding fragment thereof comprising a VH domain sequence comprising 0 to 5 amino acid substitutions from a reference VH having the amino acid sequence of SEQ ID NO:1.
[0055] In embodiments, the antibody formulations of the invention comprise an antibody or antigen-binding fragment thereof comprising a Vκ domain that comprises 0 to 5 amino acid substitutions from a reference Vκ having the amino acid sequence of SEQ ID NO:2.
[0056] In some embodiments, the antibody in the antibody formulation is purified before being added to the antibody formulation. The terms "isolate" and "purify" refer to the separation of the antibody from impurities or other contaminants in the composition in which the antibody is located, such as a composition containing host cell proteins. In some embodiments, the antibody is purified of at least 50%, 70%, 80%, 90%, 95%, 98%, 99%, 99.5%, or 99.9% (w / w) of impurities. For example, in some embodiments, purification of an antibody, such as an anti-IFNAR1 antibody, will include separation of the antibody from 99% (w / w) of host cell proteins originally present in the composition.
[0057] In some embodiments, the terms "isolated" and "purified" refer to separating an antibody, e.g., an anti-IFNAR1 antibody, from impurities or other contaminants in a composition to the extent consistent with guidelines of a government agency, e.g., the World Health Organization or the U.S. Food and Drug Administration.
[0058] Methods for purifying antibodies are known to those skilled in the art. Suitable techniques for carrying out purification include various types of chromatography, such as affinity chromatography, hydrophobic interaction, ion exchange (such as cation exchange chromatography or mixed mode chromatography), and filtration.
[0059] Affinity chromatography refers to a separation method whereby an antibody binds to an affinity ligand for the antibody due to its specific binding properties. A functional affinity ligand may be immobilized on a solid or semi-solid support such that when a composition containing the antibody is passed over the ligand and solid support, the antibody having a specific binding affinity for the ligand is adsorbed to the ligand, and one or more other impurities are not adsorbed (or are bound with lower affinity) and are separated from the antibody. Examples of impurities that typically do not bind (or do not bind well) include process-related impurities (e.g., host cell proteins, DNA, medium components) and some product-related impurities (e.g., antibody fragments). In some embodiments, the solid support containing the ligand is washed one or more times with a buffer to remove additional impurities before removing the adsorbed antibody from the ligand and support. After the one or more impurities are removed (eluted), the adsorbed antibody may be removed from the ligand and support, resulting in isolation of the antibody from the initial composition. Methods for removing antibodies from ligands and carriers are known to those skilled in the art depending on the ligand, and include, for example, environmental changes such as pH, addition or chaotropic or denaturing agents, or addition of commercially available elution buffers. In some embodiments, more than one affinity purification process may be used for an antibody composition. A variety of affinity ligands, including Protein A and Protein G (and combinations thereof), are known in the art. Immobilized ligands are commercially available. For example, Protein A affinity systems include MabSelect, MabSelect SuRe, MabSelect Xtra, MabSelect SuRe LX, Sepaharose CL-4B, ProSep vA, ProSep vA Ultra, and Ceramic HyperD.
[0060] Ion exchange chromatography includes cation exchange chromatography and mixed chromatography. Cation exchange chromatography refers to any method that can use a cation exchange matrix to separate antibodies and several impurities based on charge differences. The cation exchange matrix usually contains covalently attached negatively charged groups. Weak or strong cation exchange resins can be used. Strong cation exchange resins usually contain supported organic groups that contain sulfonic acid or sulfonate groups depending on the pH. Weak cation exchange resins usually contain supported organic groups that contain carboxylic acid or carboxylate groups depending on the pH. In certain embodiments, multimodal cation exchange resins can be utilized that incorporate additional binding mechanisms and one or more ionic interactions, such as hydrogen bonding interactions and hydrophobic interactions. Examples of suitable cation exchange resins are well known in the art and include, but are not limited to, Fractogel, carboxymethyl (CM), sulfoethyl (SE), sulfopropyl (SP), phosphate (P) and sulfonate (S), PROPAC WCX-10™ (Dionex), Capto S, S-Sepharose FF, Fractogel EMD SO3M, Toyopearl Megacap II SP 550C, Poros 50 HS, and SP-Sepharose Matrix. In some embodiments, more than one cation exchange chromatography process may be used for the composition.
[0061] Mixed-mode chromatography refers to a method that utilizes two or more forms of interaction between the stationary phase and the analyte to achieve separation of the analyte from impurities (e.g., host cell proteins, process-related impurities such as DNA, and / or endogenous or adventitious viruses). Examples of suitable anion exchange matrices are known in the art and include, but are not limited to, Capto Adhere, Sartobind Q, Natrix Q, Chromasorb Q, and Mustang Q.
[0062] In some embodiments, additional filtration steps can be used to remove impurities. For example, in some embodiments, nanofiltration or ultrafiltration is used. Nanofiltration involves passing the composition through a matrix with a pore size of, for example, less than 75 nm, less than 50 nm, and even less than 15 nm, to separate impurities, such as viruses, from antibodies. Commercially available nanofilters and ultrafilters that can be used are manufactured by various suppliers, such as Millipore Corporation (Billerica, Mass., e.g., Viresolve Pro and Viresolve Pro+), Pall Corporation (East Hills, NY), GE Healthcare Sciences (Piscataway, NJ), and Sartorius Corporation (Goettingen, Germany).
[0063] In some embodiments, an antibody used in a formulation of the invention, e.g., an anti-IFNAR or antigen-binding fragment thereof, comprises a Kabat-defined VH sequence of SEQ ID NO: 1 and a Kabat-defined Vκ of SEQ ID NO: 2, and the antibody is administered at a concentration of 10 mg / ml to 300 mg / ml, 30 mg / ml to 250 mg / ml, 50 mg / ml to 200 mg / ml, 100 mg / ml to 200 mg / ml, 125 mg / ml to 175 mg / ml, 130 mg / ml to 170 mg / ml, 135 mg / ml to 165 mg / ml, and are present in formulations at concentrations of 140mg / ml-160mg / ml, 145mg / ml-155mg / ml, 130mg / ml, 135mg / ml, 140mg / ml, 145mg / ml, 146mg / ml, 147mg / ml, 148mg / ml, 149mg / ml, 150mg / ml, 151mg / ml, 152mg / ml, 153mg / ml, 154mg / ml, 155mg / ml, 156mg / ml, 157mg / ml, 158mg / ml, 159mg / ml or 160mg / ml. In some embodiments, the antibody is at a concentration of about 50 mg / ml, 55 mg / ml, 60 mg / ml, 65 mg / ml, 70 mg / ml, 75 mg / ml, 80 mg / ml, 85 mg / ml, 90 mg / ml, 95 mg / ml, 100 mg / ml, 125 mg / ml, 130 mg / ml, 140 mg / ml, 150 mg / ml, 160 mg / ml, 170 mg / ml, 180 mg / ml, 190 mg / ml, 200 mg / ml.
[0064] The antibody formulation of the present invention contains lysine. [ka] Lysine is an essential amino acid having the structure: As used herein, lysine may include the free base form of lysine and any and all salts thereof. In embodiments, the salt forms of lysine are lysine acetate, lysine monochloride, lysine dichloride, lysine L-aspartate, and lysine L-glutamate. In some embodiments, lysine includes its pharma- ceutically acceptable salts. For example, lysine includes lysine hydrochloride. Lysine, as used herein, also includes all enantiomers (e.g., L-lysine and S-lysine), and any combination of enantiomers (e.g., 50% L-lysine and 50% S-lysine; 90%-100% L-lysine and 10%-0% S-lysine, etc.). In some embodiments, the term "lysine" includes greater than 99% L-lysine and less than 1% S-lysine. In some embodiments, the term "lysine" includes enantiomerically pure L-lysine. In some embodiments, the lysine is pharmaceutical grade lysine.
[0065] In an embodiment, the antibody formulation of the present invention contains about 10 to about 100 mM lysine, about 20 to about 90 mM lysine, about 30 mM lysine to about 80 mM lysine, about 40 to about 70 mM lysine, about 45 to about 65 mM lysine, about 45 to about 60 mM lysine, or about 50 to about 55 mM lysine in the antibody formulation, for example, an antibody formulation containing 100 to 200 mg / mL antibody, or about 150 mg / mL antibody. In an embodiment, the formulation of the present invention contains about 50 mM lysine HCl, 100 to 200 mg / mL antibody, or about 150 mg / mL antibody, an uncharged excipient, a surfactant, and a formulation buffer.
[0066] The antibody formulations of the present invention may include non-charged excipients. The term excipient refers to a pharmacologically inactive substance that is formulated with the antibody described herein. In some embodiments, the excipient may help prevent denaturation or otherwise stabilize the antibody. Suitable excipients that may be used in pharmaceutical compositions are known in the art. Examples can be found, for example, in the manual Gennaro, Alfonso R.: "Remington's Pharmaceutical Sciences", Mack Publishing Company, Easton, Pa., 1990. In some embodiments, the excipient is an "uncharged" excipient, i.e., an excipient that does not carry either a positive "+" or a negative "-" charge. In some embodiments, the excipient is selected from the group consisting of fructose, glucose, mannose, sorbose, xylose, lactose, maltose, sucrose, dextran, pullulan, dextrin, cyclodextrin, soluble starch, trehalose, sorbitol, erythritol, isomalt, lactitol, maltitol, xylitol, glycerol, lactitol, hydroxyethyl starch, and water soluble glucan.
[0067] In some embodiments, the uncharged excipient is present in the antibody formulation at about 1 mM to about 1 M, about 2 mM to about 500 mM, about 5 mM to about 400 mM, about 10 mM to about 300 mM, or about 20 mM to about 250 mM. In some embodiments, the uncharged excipient is present in the antibody formulation at about 30 mM to about 230 mM, about 40 mM to about 220 mM, about 50 mM to about 210 mM, about 60 mM to about 210 mM, about 70 mM to about 200 mM, about 70 mM to about 200 mM, about 70 mM to about 200 mM, about 80 mM to about 190 mM, about 90 mM to about 180 mM, about 100 mM to about 250 mM, or about 250 mM. In one embodiment, the uncharged excipient is present in the antibody formulation at about 100 mM to about 170 mM, about 110 mM to about 160 mM, about 12 mM to about 150 mM, about 125 mM to about 145 mM, about 125 mM to about 140 mM, about 120 mM, about 125 mM, about 130 mM, about 135 mM, about 140 mM, about 150 mM, about 160 mM, or about 170 mM, e.g., the antibody formulation contains 100 to 200 mg / mL antibody. In one embodiment, the uncharged excipient is present in the antibody formulation at about 130 mM. In some embodiments, the uncharged excipient is present in the antibody formulation at about 50 mM to about 500 mM, about 100 mM to about 450 mM, about 110 mM to about 350 mM, about 120 mM, about 125 mM, about 130 mM, about 140 mM, or about 145 mM, e.g., the antibody formulation contains 100-200 mg / mL antibody or about 150 mg / mL antibody. In one embodiment, the uncharged excipient is present in the antibody formulation at about 130 mM.
[0068] In some embodiments, the uncharged excipient has the formula: [ka] and trehalose, represented by the formula:
[0069] In some embodiments, trehalose is present in the antibody formulation at about 1 mM to about 1 M, about 2 mM to about 500 mM, about 5 mM to about 400 mM, about 10 mM to about 300 mM, or about 20 mM to about 250 mM. In some embodiments, trehalose is present in the antibody formulation at about 30 mM to about 230 mM, about 40 mM to about 220 mM, about 50 mM to about 210 mM, about 60 mM to about 210 mM, about 70 mM to about 200 mM, about 80 mM to about 190 mM, about 90 mM to about 180 mM, about 100 mM to about 170 mM, about 110 mM to about In one embodiment, trehalose is present in the antibody formulation at about 160 mM, about 120 mM to about 150 mM, about 125 mM to about 145 mM, about 125 mM to about 140 mM, about 120 mM, about 125 mM, about 130 mM, about 135 mM, about 140 mM, about 150 mM, about 160 mM, or about 170 mM, for example, the antibody formulation contains 100 to 200 mg / mL antibody. In some embodiments, trehalose is present in the antibody formulation at about 50 mM to about 500 mM, about 100 mM to about 450 mM, about 110 mM to about 350 mM, about 120 mM, about 125 mM, about 130 mM, about 140 mM, or about 145 mM, e.g., the antibody formulation contains 100-200 mg / mL antibody or about 150 mg / mL antibody. In one embodiment, trehalose is present in the antibody formulation at about 130 mM.
[0070] The antibody formulation may include various other components. In some embodiments, the antibody formulation may include a buffer (e.g., histidine, acetate, phosphate or citrate buffer), and / or a stabilizer (e.g., human albumin), etc. In some embodiments, the antibody formulation may include a pharma- ceutically acceptable carrier, including, for example, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, sucrose, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, polyethylene-polyoxypropylene-block polymers, and polyethylene glycol.
[0071] In some embodiments, the antibody formulation further comprises a surfactant, hi some embodiments, the surfactant is selected from the group consisting of Triton X-100, Tween 80, polysorbate 20, polysorbate 80, nonoxynol-9, poloxamer, stearyl alcohol, sodium dodecyl sulfate, and sorbitan monostearate.
[0072] In some embodiments, the surfactant has the formula: [ka] and polysorbate 80, i.e., polyoxyethylene (20) sorbitan monooleate, represented by: Polysorbate 80 (PS-80) is available from several commercial suppliers, e.g., Alkest® TW80 (Univar®), and Tween® 80 (Sigma-Aldrich®). Applicants have found that, in some cases, adjusting the concentration of PS-80 in an antibody formulation increases stability and reduces the amount of particle formation upon extended storage.
[0073] In some embodiments, PS-80 is about 0.01% to about 0.1%, about 0.02% to about 0.09%, about 0.02% to about 0.08%, about 0.03% to about 0.08%, about 0.04% to about 0.07%, about 0.05% to about 0.06%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06% to about 0.07% of the antibody formulation, e.g., an antibody formulation containing about 100 mg / mL to about 200 mg / mL of antibody or about 150 mg / mL of antibody. In some embodiments, PS-80 is about 0.05% in the antibody formulation.
[0074] In some embodiments, the antibody formulation further comprises a histidine / histidine HCl buffer. In some embodiments, the antibody formulation comprises about 1 mM to about 100 mM, about 5 mM to about 80 mM histidine / histidine HCl buffer, about 10 mM to about 60 mM histidine / histidine HCl buffer, about 15 mM to about 50 mM histidine / histidine HCl buffer, about 15 mM to about 30 mM histidine / histidine HCl buffer, or about 25 mM histidine / histidine HCl buffer in the antibody formulation of the present invention, for example, an antibody formulation comprising 100 to 200 mg / mL antibody or about 150 mg / mL antibody. In one embodiment, the histidine / histidine HCl buffer is about 25 mM in the antibody formulation.
[0075] In some embodiments, the invention is directed to an antibody formulation comprising 150 mg / mL anifrolumab or an antigen-binding fragment thereof; 50 mM lysine HCl; 130 mM uncharged excipients; 0.05% surfactant; and 25 mM formulation buffer, wherein the formulation has a pH of about 5.9.
[0076] In some embodiments, the invention is directed to an antibody formulation comprising 150 mg / mL anifrolumab; 50 mM lysine HCl; 130 mM uncharged excipients; 0.05% surfactant; 25 mM formulation buffer, wherein the formulation has a pH of about 5.9.
[0077] In an additional embodiment, the invention is directed to an antibody formulation comprising 150 mg / mL anifrolumab; 50 mM Lysine HCl; 130 mM Trehalose dihydrate; 0.05% Polysorbate 80; 25 mM Histidine / Histidine HCl, wherein the formulation has a pH of 5.9.
[0078] In some embodiments, the invention is directed to a stable antibody formulation comprising (a) about 100 mg / mL to about 200 mg / mL of an antibody or antigen-binding fragment thereof, (b) about 0.02% to about 0.1% polysorbate 80, (c) about 100 mM to about 160 mM trehalose, (d) about 40 mM to about 60 mM L-lysine HCl, and (e) 15 to 35 mM histidine / histidine HCl, wherein the antibody is anifrolumab. In embodiments, the formulation pH is about 5.5 to about 6.5.
[0079] In a further embodiment, the invention is directed to a stable antibody formulation comprising (a) about 145 mg / mL to about 155 mg / mL of an antibody or antigen-binding fragment thereof, (b) about 0.04% to about 0.08% polysorbate 80, (c) about 120-140 mM trehalose dihydrate, (d) about 45-55 mM L-lysine HCl, and (e) about 20-30 mM histidine / histidine HCl, wherein the antibody is anifluromab. In an embodiment, the formulation pH is about 5.8 to about 6.1.
[0080] In a further embodiment, the invention is directed to a stable antibody formulation comprising: (a) about 150 mg / mL of an antibody or antigen-binding fragment thereof, (b) about 0.05% polysorbate 80, (c) about 130 mM trehalose dihydrate, (d) about 50 mM L-lysine HCl, and (e) about 25 mM histidine / histidine HCl, wherein the antibody is anifluromab. In an embodiment, the formulation pH is about 5.9.
[0081] In some embodiments, the invention is directed to an antibody formulation comprising 150 mg / mL anifrolumab or an antigen-binding fragment thereof; 50 mM Lysine HCl; 130 mM Trehalose dihydrate; 0.05% Polysorbate 80; 25 mM Histidine / Histidine HCl, wherein the formulation has a pH of about 5.9.
[0082] In an additional embodiment, the invention is directed to an antibody formulation comprising 150 mg / mL anifrolumab; 50 mM Lysine HCl; 130 mM Trehalose dihydrate; 0.05% Polysorbate 80; 25 mM Histidine / Histidine HCl, wherein the formulation has a pH of 5.9.
[0083] In some embodiments, various components can be omitted from the antibody formulations or the antibody formulations are "substantially free" of the component. The term "substantially free," as used herein, refers to an antibody formulation that contains less than 0.01%, less than 0.001%, less than 0.0005%, less than 0.0003%, or less than 0.0001% of the specified component.
[0084] Antibody formulations can have different osmolalities. Methods for measuring the osmolality of antibody formulations are known to those of skill in the art, including, for example, an osmometer (e.g., Advanced Instrument Inc 2020 Freezing Point Depression Osmometer). In some embodiments, the formulation has an osmolality of 200-600 mosm / kg, 260-500 mosm / kg, or 300-450 mosm / kg.
[0085] The antibody formulations of the present invention may have a variety of pH levels. In some embodiments, the pH of the antibody formulation is 4-7, 4.5-6.5, or 5-6. In some embodiments, the pH of the antibody formulation is 5.0. In some embodiments, the pH of the antibody formulation is 6.0. In some embodiments, the pH of the antibody formulation is ≦7.0. Various means may be utilized to obtain the desired pH level, including, but not limited to, the addition of an appropriate buffer.
[0086] The antibody formulations described herein have a variety of viscosities. Methods for measuring the viscosity of antibody formulations are known to those skilled in the art, including, for example, a rheometer (e.g., an Anton Paar MCR301 rheometer with a 50 mm, 40 mm, or 20 mm plate attachment). In some embodiments of the present invention, the viscosity is reported at the high shear limit of 1000 shear rates per second. In some embodiments, the antibody formulation has a viscosity of less than 20 centipoise (cP), less than 18 cP, less than 15 cP, less than 13 cP, or less than 11 cP. In some embodiments, the antibody formulation has a viscosity of less than 13 cP. Those skilled in the art will understand that viscosity is dependent on temperature, and thus, unless otherwise specified, the viscosities provided herein are measured at 25° C. unless otherwise specified.
[0087] The injection force correlates with the resistance provided by the antibody formulation when it is administered to a subject. The injection force depends on the gauge and temperature of the administration needle. In some embodiments, the antibody formulation has an injection force of less than 15N, 12N, 10N, or 8N when passing through a 27Ga subarachnoid thin-walled (STW) needle. In some embodiments, the antibody formulation has an injection force of less than 15N, 12N, 10N, or 8N when passing through a 29Ga STW needle.
[0088] In additional embodiments, the antibody formulations of the present invention are aqueous solutions. In some embodiments, the antibody formulations have not been exposed to freezing temperatures and / or frozen, i.e., they have remained in a liquid state. In some embodiments, the antibody in the antibody formulation has not been lyophilized.
[0089] As used herein, the term stability generally relates to maintaining the integrity of a bioactive agent, such as a protein, peptide, or another bioactive macromolecule, or minimizing degradation, denaturation, aggregation, or unfolding. As used herein, "improved stability" generally means that a protein of interest (e.g., an antibody such as anifrolumab), peptide, or another bioactive macromolecule maintains greater stability compared to a control protein, peptide, or another bioactive macromolecule under conditions known to result in degradation, denaturation, aggregation, or unfolding.
[0090] In some embodiments, stability refers to an antibody formulation having low to undetectable levels of particle formation. The phrase "low to undetectable levels of particle formation" as used herein refers to samples containing less than 1000 particles / mL, less than 700 particles / mL, less than 650 particles / mL, less than 500 particles / mL, less than 400 particles / mL, less than 200 particles / mL, less than 100 particles / mL, or less than 1 / mL particles after storage for about 18 months at about 40° C., as determined by HIAC analysis or visual analysis in which particles greater than 10 microns in size are detected. In some embodiments, no particles are detected in the antibody formulation by either HIAC analysis or visual analysis.
[0091] In some embodiments, stability refers to a reduction in antibody fragmentation. In embodiments, the fragmentation rate of an antibody, such as anifrolumab, in a formulation of the invention is about 2.0-4.0% per month over 12 months as determined by HP-SEC analysis performed on an Agilent HPLC instrument equipped with a TSK-Gel G3000 column. In embodiments, the fragmentation rate of an antibody, such as anifrolumab, in a formulation of the invention is about 2.0-4.0% per month over 6 months as determined by HP-SEC analysis performed on an Agilent HPLC instrument equipped with a TSK-Gel G3000 column. In embodiments, the fragmentation rate of an antibody, such as anifrolumab, in a formulation of the invention is about 2.0-4.0% per month over 2 months as determined by HP-SEC analysis performed on an Agilent HPLC instrument equipped with a TSK-Gel G3000 column. In embodiments, the fragmentation rate of an antibody, such as anifrolumab, in a formulation of the invention is about 3.0-4.0% per month over a two month period as determined by HP-SEC analysis performed on an Agilent HPLC instrument equipped with a TSK-Gel G3000 column.
[0092] In further embodiments, stability refers to reduced aggregation of the antibody. In an embodiment, for example, the aggregation rate of the antibody formulation of the present invention containing anilorumab is about 0.5-2.5% per month over 12 months as determined by HP-SEC analysis performed on an Agilent HPLC system equipped with a TSK-Gel G3000 column. In an embodiment, for example, the aggregation rate of the antibody formulation of the present invention containing anilorumab is about 0.5-2.5% per month over 6 months as determined by HP-SEC analysis performed on an Agilent HPLC system equipped with a TSK-Gel G3000 column. In an embodiment, for example, the aggregation rate of the antibody formulation of the present invention containing anilorumab is about 0.5-2.5% per month over 2 months as determined by HP-SEC analysis performed on an Agilent HPLC system equipped with a TSK-Gel G3000 column. In additional embodiments, for example, an antibody formulation of the invention containing anilorumab has an aggregation rate of about 1-2% per month over a two month period as determined by HP-SEC analysis performed on an Agilent HPLC instrument equipped with a TSK-Gel G3000 column.
[0093] In further embodiments, stability refers to reduced purity loss. In an embodiment, for example, the purity loss rate of the antibody formulation of the present invention containing anilorumab is about 3-5% per month over 12 months as determined by HP-SEC analysis performed on an Agilent HPLC system equipped with a TSK-Gel G3000 column. In an embodiment, for example, the purity loss rate of the antibody formulation of the present invention containing anilorumab is about 3-5% per month over 6 months as determined by HP-SEC analysis performed on an Agilent HPLC system equipped with a TSK-Gel G3000 column. In an additional embodiment, for example, the purity loss rate of the antibody formulation of the present invention containing anilorumab is about 3.5-4.5% per month over 2 months as determined by HP-SEC analysis performed on an Agilent HPLC system equipped with a TSK-Gel G3000 column.
[0094] Those skilled in the art will appreciate that protein stability depends on other properties in addition to the formulation composition. For example, stability can be affected by temperature, pressure, humidity, pH, and external forms of radiation. Thus, unless otherwise noted, stability referred to herein is considered to be measured at 40° C., 1 atm, 50% relative humidity, pH 6.0, and standard background levels of radiation. Antibody stability in antibody formulations can be determined by various means. In some embodiments, antibody stability is determined by size exclusion chromatography (SEC). SEC separates analytes (e.g., macromolecules such as proteins and antibodies) based on a combination of their hydrodynamic size, diffusion coefficient, and surface properties. Thus, for example, SEC can separate antibodies in their native three-dimensional conformation from antibodies in various denatured states and / or degraded antibodies. In SEC, the stationary phase is generally composed of inert particles packed into a dense three-dimensional matrix in a glass or steel column. The mobile phase can be pure water, aqueous buffers, organic solvents, mixtures of these, or other solvents. Stationary phase particles have small pores and / or channels that only allow entry to chemical species below a certain size. Larger particles are therefore excluded from these pores and channels, while smaller particles are removed from the flowing mobile phase. The time that particles remain immobilized within the stationary phase pores depends in part on how far they have penetrated into the pores. By being removed from the mobile phase stream, they take longer to elute from the column, resulting in separation between particles based on size differences.
[0095] In some embodiments, SEC is combined with identification techniques to identify or characterize proteins or their fragments.Protein identification and characterization can be achieved by a variety of techniques, including but not limited to, chromatographic techniques such as high performance liquid chromatography (HPLC), immunoassays, electrophoresis, ultraviolet / visible / infrared spectroscopy, Raman spectroscopy, surface-enhanced Raman spectroscopy, mass spectrometry, gas chromatography, static light scattering (SLS), Fourier transform infrared spectroscopy (FTIR), circular dichroism (CD), urea-induced protein unfolding techniques, intrinsic tryptophan fluorescence, differential scanning calorimetry, and / or ANS protein binding.
[0096] In some embodiments, protein identification is accomplished by high pressure liquid chromatography. Various means and devices for performing HPLC are known to those skilled in the art. In general, HPLC involves loading a liquid solvent containing the protein of interest into a separation column in which separation occurs. The HPLC separation column is filled with solid particles (e.g., silica, polymer, or adsorbent), and the sample mixture is separated into compounds following interaction with the column particles. HPLC separation is affected by liquid solvent conditions (e.g., pressure, temperature), chemical interactions between the sample mixture and the liquid solvent (e.g., hydrophobicity, protonation, etc.), and chemical interactions between the sample mixture and the solid particles packed in the separation column (e.g., ligand affinity, ion exchange, etc.).
[0097] In some embodiments, SEC and protein identification are performed in the same instrument or simultaneously, for example, SEC and HPLC may be combined, often referred to as HP-SEC.
[0098] In some embodiments, the antibody formulation comprises about 100 mg / ml to about 200 mg / ml antibody or antigen-binding fragment thereof and is stable upon storage at about 40° C. for 1 to 24 months, and the antibody is anifrolumab. In some embodiments, the formulation is stable upon storage at about 25° C. for 1 to 18 months. In some embodiments, the formulation is stable upon storage at about 5° C. for 1 to 6 months. In some embodiments, the formulation is stable upon storage at about 5° C. for 1 to 3 months. In some embodiments, the formulation is stable upon storage at about 5° C. for 1 to 12 months. In some embodiments, the formulation is stable upon storage at about 5° C. for at least 18 months. In some embodiments, the formulation is stable upon storage at about 5° C. for at least 24 months or 36 months.
[0099] The term "stable" can be relative and not absolute. Thus, in some embodiments, an antibody is stable if less than 20%, 15%, 10%, 5% or 2% of the antibody is degraded, denatured, aggregated or unfolded when stored at 2°C-8°C for 6 months as measured by HP-SEC. In some embodiments, an antibody is stable if less than 20%, 15%, 10%, 5% or 2% of the antibody is degraded, denatured, aggregated or unfolded when stored at 2°C-8°C for 12 months as measured by SEC HPLC. In some embodiments, an antibody in an antibody formulation is stable if less than 20%, 15%, 10%, 5% or 2% of the antibody is degraded, denatured, aggregated or unfolded when stored at 2°C-8°C for 18 months as measured by HP-SEC. In some embodiments, the antibody in the antibody formulation is stable if, when the antibody is stored at 2° C.-8° C. for 24 months, less than 20%, less than 15%, less than 10%, less than 5%, or less than 2% of the antibody is degraded, denatured, aggregated, or unfolded as measured by SEC HPLC.
[0100] In some embodiments, an antibody is stable if less than 20%, 15%, 10%, 5% or 2% of the antibody is degraded, denatured, aggregated or unfolded when stored at 23° C.-27° C. for 3 months as measured by HP-SEC. In some embodiments, an antibody is stable if less than 20%, 15%, 10%, 5% or 2% of the antibody is degraded, denatured, aggregated or unfolded when stored at 23° C.-27° C. for 6 months as measured by HP-SEC. In some embodiments, an antibody is stable if less than 20%, 15%, 10%, 5% or 2% of the antibody is degraded, denatured, aggregated or unfolded when stored at 23° C.-27° C. for 12 months as measured by HP-SEC. In some embodiments, an antibody is stable if, when stored at 23° C.-27° C. for 24 months, less than 20%, less than 15%, less than 10%, less than 5%, or less than 2% of the antibody is degraded, denatured, aggregated, or unfolded as measured by HP-SEC.
[0101] In some embodiments, an antibody is stable if less than 6%, 4%, 3%, 2%, or 1% of the antibody degrades, denatures, aggregates, or unfolds per month as measured by HP-SEC when stored at 40° C. In some embodiments, an antibody is stable if less than 6%, 4%, 3%, 2%, or 1% of the antibody degrades, denatures, aggregates, or unfolds per month as measured by HP-SEC when stored at 5° C.
[0102] In embodiments, an antibody is stable if, when stored at 5° C., less than 1%, 2%, 3%, 4%, 5% or 6% (or about 1%-6%) of the antibody degrades, denatures, aggregates or unfolds per month over 1-3 months, 1-6 months, 1-12 months, 1-18 months, or 1-24 months as determined by HP-SEC.
[0103] In some embodiments, an antibody formulation of the present invention may be considered stable if the antibody exhibits very little or no decrease in the binding activity of the antibody (including its antibody fragment) of the formulation compared to a reference antibody over a period of 8 weeks, 4 months, 6 months, 9 months, 12 months, or 24 months, as measured by an antibody binding assay known to those skilled in the art, such as, for example, ELISA. In some embodiments, an antibody stored at about 40° C. for at least one month retains at least 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, or at least about 99% of its binding ability to an INFAR1 receptor polypeptide compared to a reference antibody that has not been stored. In some embodiments, an antibody stored at about 5° C. for at least six months retains at least 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, or at least about 99% of its binding ability to an INFAR1 receptor polypeptide compared to a reference antibody that has not been stored. In some embodiments, an antibody stored at about 40° C. for at least one month retains at least 95% of its ability to bind to an INFAR1 receptor polypeptide compared to a reference antibody that has not been stored. In some embodiments, an antibody stored at about 5° C. for at least six months retains at least 95% of its ability to bind to an INFAR1 receptor polypeptide compared to a reference antibody that has not been stored.
[0104] Applicants have found that the antibody formulations provided herein result in significantly reduced particle formation as determined by visual inspection, microflow imaging (MFI), or size exclusion chromatography (SEC).
[0105] In some embodiments, the formulation is substantially free of particles, as determined by visual inspection, upon storage for at least 1 month at about 40° C. In some embodiments, the formulation is substantially free of particles, as determined by visual inspection, upon storage for at least 6 months, at least 9 months, at least 12 months, at least 15 months, at least 18 months, at least 24 months, or at least 36 months at about 5° C.
[0106] In some embodiments, the antibody formulations of the present invention may be used for pharmaceutical purposes. Antibodies used for pharmaceutical purposes must generally have a high level of purity, particularly with respect to contaminants from cell cultures, including cellular protein contaminants, cellular DNA contaminants, viruses and other infectious agents. See "WHO Requirements for the use of animal cells as in vitro substrates for the production of biologicals: Requirements for Biological Substances No. 50." No. 878. Annex 1, 1998. In response to concerns about contaminants, the World Health Organization (WHO) has set limits for the levels of various contaminants. For example, the WHO recommends a DNA tolerance limit of less than 10 ng per dose of protein products. Similarly, the U.S. Food and Drug Administration (FDA) sets a DNA tolerance limit of 0.5 pg / mg protein or less. Thus, in some embodiments, the present invention is directed to antibody formulations that meet or exceed the contaminant limits set by one or more government agencies, such as, for example, the U.S. Food and Drug Administration and / or the World Health Organization.
[0107] In some embodiments, the anti-antibody formulations described herein are pharma- ceutically acceptable. "Pharmaceutically acceptable" refers to antibody formulations that are, within the scope of sound medical judgment, suitable for contact with human and animal tissues without excessive toxicity or other complications, commensurate with a reasonable benefit / risk ratio.
[0108] The purity of the antibody preparation may vary. In some embodiments, the therapeutic antibody of interest, such as an anti-INFAR1 antibody, is greater than 90% (wt / wt) of the total polypeptides present in the antibody preparation. In some embodiments, the therapeutic antibody of interest, such as an anti-INFAR1 antibody, is greater than 95% (wt / wt), 98% (wt / wt), 99% (wt / wt), 99.5% (wt / wt) or 99.9% (wt / wt) of the total polypeptides present in the antibody preparation.
[0109] The present invention further provides a method for treating a type I IFN-mediated disease or disorder in a subject in need thereof by administering a therapeutically effective amount of the antibody formulation described herein.In an embodiment, the disease or disorder is selected from the group consisting of systemic lupus erythematosus (SLE), insulin-dependent diabetes mellitus, inflammatory bowel disease, multiple sclerosis, psoriasis, autoimmune thyroiditis, rheumatoid arthritis, glomerulonephritis, scleroderma, myositis, and lupus nephritis.In a further embodiment, the disease or disorder is an inflammatory bowel disease, such as Crohn's disease, ulcerative colitis, and celiac disease.In a further embodiment, the disease or disorder is a pulmonary disease or a disorder, such as systemic lupus erythematosus.
[0110] The antibody formulations of the present invention may be administered to a subject through a variety of means. In some embodiments, the antibody formulations are suitable for parenteral administration, for example, via inhalation (e.g., powder or aerosol spray), transmucosal, intravenous, subcutaneous, or intramuscular administration. In some embodiments, the formulation is an injectable formulation. In some embodiments, the present invention is directed to a sealed container comprising any of the antibody formulations as described herein.
[0111] In some aspects, the present invention is directed to various pharmaceutical dosage forms. Various dosage forms may be applied to the formulations provided herein. See, for example, Pharmaceutical Dosage Form: Parenteral Medications, Volume 1, 2nd Edition. In one embodiment, the pharmaceutical unit dose of the present invention comprises an antibody formulation in a suitable container, such as, for example, a vial or a syringe. In one embodiment, the pharmaceutical unit dose of the present invention comprises an antibody formulation delivered intravenously, subcutaneously, or intramuscularly. In another embodiment, the pharmaceutical unit dose of the present invention comprises an antibody formulation delivered by an aerosol. In a particular embodiment, the pharmaceutical unit dose of the present invention comprises an antibody formulation delivered subcutaneously. In another embodiment, the pharmaceutical unit dose of the present invention comprises an antibody formulation delivered by an aerosol. In a further embodiment, the pharmaceutical unit dose of the present invention comprises an antibody formulation administered intranasally.
[0112] The antibody formulations of the present invention may be prepared as unit dose dosage forms by preparing vials containing aliquots of the aqueous antibody formulation for single use. For example, a unit dose per vial may contain different concentrations of 1 ml, 2 ml, 3 ml, 4 ml, 5 ml, 6 ml, 7 ml, 8 ml, 9 ml, 10 ml, 15 ml, or 20 ml of an antibody that specifically binds to the INFAR1 receptor, ranging from about 0.1 mg / ml to about 300 mg / ml. If necessary, these formulations may be adjusted to the desired concentration by adding a sterile diluent to each vial. In certain embodiments, the aqueous antibody formulations of the present invention are formulated into single dose vials as a sterile liquid containing about 2 mg / ml to about 20 mg / ml of an antibody or antigen-binding fragment thereof, and the antibody is anifrolumab. In another specific embodiment, the aqueous antibody formulation of the invention is formulated in a single dose vial as a sterile liquid containing about 100 mg / ml to about 200 mg / ml of an antibody or antigen-binding fragment thereof, about 45-55 mM Lysine HCl, about 0.04% to about 0.08% Polysorbate 80, about 120 mM to about 140 mM Trehalose, and about 20-30 mM Histidine / Histidine HCl, and the antibody is anifrolumab. In an embodiment, the pH of the formulation is about 6. In one embodiment, the antibody of the invention is provided at 140-160 mg / ml in a 3 cc USP Type I amber borosilicate vial (West Pharmaceutical Services part number 6800-0675). In another embodiment, the antibody of the invention is provided at 150 mg / ml in a 3 cc USP Type I amber borosilicate vial.
[0113] The antibody formulation of the present invention can be prepared as a unit dose dosage form by preparing a pre-filled syringe containing an aliquot of the aqueous antibody formulation for single use.For example, a unit dose per pre-filled syringe may contain various concentrations of 0.1ml, 0.2ml, 0.3ml, 0.4ml, 0.5ml, 0.6ml, 0.7ml, 0.8ml, 0.9ml, 1ml, 2ml, 3ml, 4ml, 5ml, 6ml, 7ml, 8ml, 9ml, 10ml, 15ml, or 20ml of the antibody or antigen-binding fragment thereof that specifically binds to IFNAR1 polypeptide in the range of about 140mg / ml to about 160mg / ml. In a particular embodiment, the aqueous antibody formulation of the invention is formulated in a single-dose pre-filled syringe as a sterile liquid containing about 145 mg / mL to about 155 mg / mL of an antibody or antigen-binding fragment thereof, about 45-55 mM lysine HCl, about 0.04% to about 0.08% polysorbate 80, about 120 mM to about 140 mM trehalose, and about 20-30 mM histidine / histidine HCl, and the antibody is anifrolumab. In an embodiment, the pH of the formulation is about 6. In a particular embodiment, the aqueous antibody formulation of the invention is formulated in a single-dose pre-filled syringe as a sterile liquid containing about 145 mg / mL to about 155 mg / mL of an antibody or antigen-binding fragment thereof, about 45-55 mM lysine HCl, about 0.04% to about 0.08% polysorbate 80, about 120 mM to about 140 mM trehalose, and about 20-30 mM histidine / histidine HCl, and the antibody is anifrolumab. In an embodiment, the pH of the formulation is about 6.
[0114] Various doses can be administered in a single use. For example, in some embodiments, 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 12 mg, 14 mg, 16 mg, 18 mg, 20 mg, 30 mg, 40 mg, 50 mg, 70 mg, or 100 mg of antibody can be administered in a single dose.
[0115] Various types of syringes may be used. The syringe may be filled with the antibody formulation immediately before administration to the subject, such as, for example, 1 week, 1 day, 6 hours, 3 hours, 2 hours, 1 hour, 30 minutes, 20 minutes, or less than 10 minutes before administration to the subject. In some embodiments, the syringe is filled with the antibody formulation at the point of retail sale or by the facility where the treatment of the subject is performed. In some embodiments, the syringe is pre-filled, for example, the syringe is filled with the antibody formulation 1 day, 2 days, 4 days, 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months, 18 months, 24 months, 3 years, or 4 years or more before administration to the subject. In some embodiments, the pre-filled syringe includes a needle, such as, for example, a 27G regular needle, a 27G thin-walled needle, a 29G regular needle, or a 29G thin-walled needle. In some embodiments, the pre-filled syringe includes a 27G thin-walled needle for intrathecal puncture.
[0116] In some embodiments, any syringe suitable for administration to desired subject may be used.In some embodiments, the syringe is a plastic syringe or a glass syringe.In some embodiments, the syringe is made of a material that is substantially free of tungsten.In some embodiments, the syringe is coated with silicone.In some embodiments, the pre-filled syringe comprises a plunger with a fluoropolymer resin disk. Examples of syringes include, but are not limited to, BD Hypak™ SCF 1MLL 27G1 / 2-5B BD260L WL, 0.4mg silicone oil MDN with 27G STW needle; Hypak™ for Biotech 1ml Long with Becton Dickinson Hypak 1mL long plunger stopper 4023 (Becton Dickinson); Flurotec Daikyo Si1000 (catalog number 47271919); C3Pin; Hypak™ for Biotech 0.8mg silicone oil (Becton Dickinson); and CZ syringes (West, catalog number 19550807).
[0117] The aqueous antibody formulations of the invention may be sterilized by a variety of sterilization methods, including sterile filtration, radiation, etc. In certain embodiments, the diafiltered antibody formulations are sterile filtered through a sterile 0.2 micron filter. The sterile aqueous antibody formulations of the invention may be administered to a subject to prevent, treat and / or manage an immune response, such as, for example, an inflammatory response.
[0118] The present invention further provides a pre-filled syringe containing the antibody formulation of the subject invention. In some embodiments, the pre-filled syringe contains (a) about 100 mg / mL to about 200 mg / mL of an anti-IFNAR1 antibody, about 25 mM to 130 mM of lysine or a lysine salt, an uncharged excipient, a surfactant, and a formulation buffer.
[0119] The present invention further provides a pre-filled syringe containing the antibody formulation of the subject invention. In some embodiments, the pre-filled syringe contains (a) about 100 mg / mL to about 200 mg / mL of anifrolumab or an antigen-binding fragment thereof, about 40 to 60 mM lysine HCl, about 100 mM to about 160 mM trehalose dihydrate, 0.02% to about 0.1% polysorbate 80, and about 15 mM to about 35 mM histidine / histidine HCl. In an embodiment, the pH of the formulation is about 5.5 to about 6.5.
[0120] The present invention further provides a pre-filled syringe containing the antibody formulation of the subject invention. In some embodiments, the pre-filled syringe contains (a) about 145 mg / mL to about 155 mg / mL of anifrolumab or an antigen-binding fragment thereof, about 45 to 55 mM lysine HCl, 120 mM to about 140 mM trehalose dihydrate, 0.04% to about 0.08% polysorbate 80, and 20 mM to about 30 mM histidine / histidine HCl. In an embodiment, the pH of the formulation is about 5.8 to 6.1.
[0121] The present invention further provides a pre-filled syringe comprising the antibody formulation of the subject invention.In some embodiments, the pre-filled syringe comprises (a) about 150mg / mL of an antibody or its antigen-binding fragment, in some embodiments, 50mM of lysine HCl, about 0.05% of polysorbate 80, about 130mM of trehalose dihydrate, and about 25mM of histidine / histidine HCl, and the antibody is anifrolumab.In some embodiments, the pH of the formulation is about 5.9.
[0122] The present invention further provides a pre-filled syringe comprising the antibody formulation of the subject invention.In some embodiments, the pre-filled syringe comprises (a) about 150mg / mL anifrolumab, about 50mM lysine HCl, about 0.05% polysorbate 80, about 130mM trehalose dihydrate, and about 25mM histidine / histidine HCl.In an embodiment, the pH of the formulation is about 5.9.
[0123] In a specific embodiment, the antibody formulation of the invention is formulated in a single-dose pre-filled syringe as a sterile liquid containing about 145 mg / mL to about 155 mg / mL of an antibody or antigen-binding fragment thereof, about 45-55 mM lysine HCl, about 0.04% to about 0.08% polysorbate 80, about 120 mM to about 140 mM trehalose, and about 20-30 mM histidine / histidine HCl, and the antibody is anifrolumab. In an embodiment, the pH of the formulation is about 6.
[0124] In an embodiment, the present invention is directed to a prefilled syringe containing an antibody formulation of the present invention, the prefilled syringe having an average sliding force of 1 to 20 N when a 27 gauge thin-walled subarachnoid puncture (STW) needle is attached. In an embodiment, the present invention is directed to a prefilled syringe containing an antibody formulation of the present invention, the prefilled syringe having an average sliding force of 5 to 15 N when a 27 gauge thin-walled subarachnoid puncture (STW) needle is attached. In an embodiment, the present invention is directed to a prefilled syringe containing an antibody formulation of the present invention, the prefilled syringe having an average sliding force of about 8 N when a 27 gauge thin-walled subarachnoid puncture (STW) needle is attached.
[0125] In some embodiments, the invention is directed to a kit comprising any of the antibody formulations described herein, the containers described herein, the unit dose forms described herein, or the pre-filled syringes described herein.
[0126] In some embodiments, the invention is also directed to a method of making a stable antibody formulation comprising an antibody, comprising the steps of: (a) purifying an antibody or antigen-binding fragment thereof to about 100 mg / mL to about 200 mg / mL, where the antibody is anifrolumab; and (b) placing the isolated antibody into a stabilized formulation to form a stable antibody formulation, the resulting stable antibody formulation comprising: (i) about 100 mg / mL to about 200 mg / mL of an antibody or antigen-binding fragment thereof that is anifrolumab; (ii) about 25 mM to about 130 mM lysine or lysine salt; (iii) about 100 mM to about 150 mM trehalose; and (iv) about 0.02% to about 0.1% polysorbate 80.
[0127] In some embodiments, the invention is also directed to a method of making a stable antibody formulation comprising an antibody, comprising the steps of: (a) purifying an antibody or antigen-binding fragment thereof to about 100 mg / mL to about 200 mg / mL, where the antibody is anifrolumab; and (b) placing the isolated antibody into a stabilized formulation to form a stable antibody formulation, the resulting stable antibody formulation comprising about 100 mg / mL to about 200 mg / mL of antibody; about 45 mM to about 55 mM lysine HCl or lysine salt; about 100 mM to about 150 mM uncharged excipient; about 0.02% to about 0.1% surfactant; and formulation buffer.
[0128] In some embodiments, the invention is also directed to a method of producing a stable antibody formulation comprising an antibody, comprising the steps of: (a) purifying an antibody or antigen-binding fragment thereof to about 145 mg / mL to about 155 mg / mL, where the antibody is anifrolumab; and (b) placing the isolated antibody into a stabilized formulation to form a stable antibody formulation, the resulting stable antibody formulation comprising about 145 mg / mL to about 155 mg / mL of antibody, about 25 mM to about 130 mM lysine HCl or lysine salt; about 120 mM to about 140 mM trehalose dihydrate; about 0.04% to about 0.08% polysorbate 80, about 20 mM to about 30 mM histidine / histidine HCl, and wherein the pH of the formulation is about 5.8 to 6.1.
[0129] In some embodiments, the present invention is directed to a method of producing a stable antibody formulation comprising the steps of: (a) purifying an antibody or antigen-binding fragment thereof to about 150 mg / mL, wherein the antibody is anifrolumab; and (b) placing the isolated antibody into a stabilized formulation to form a stable antibody formulation, wherein the resulting stable antibody formulation comprises: (i) about 150 mg / mL of the antibody or antigen-binding fragment thereof; (ii) about 50 mM lysine HCl; (iii) about 130 mM trehalose; (iv) about 0.05%% polysorbate 80, wherein the antibody is anifrolumab.
[0130] It should be noted that while many aspects of the invention are directed to aqueous formulations, for purposes of equivalents, the antibody or antibody formulation of the invention may be lyophilized if desired. Thus, the invention encompasses lyophilized forms of the formulations of the invention or lyophilized antibodies that are subsequently reconstituted into an aqueous form. In some embodiments, the invention is directed to a method of producing a reconstituted antibody or antigen-binding fragment thereof formulation comprising anifrolumab, the method comprising: (a) purifying the antibody from a cell culture; (b) lyophilizing the isolated antibody; and (c) adding the lyophilized antibody to an aqueous solution to form a reconstituted antibody formulation, the reconstituted antibody formulation comprising: (i) about 100 mg / mL to about 200 mg / mL of an antibody or antigen-binding fragment thereof that is anifrolumab; and (ii) about 45 to about 55 mM lysine HCl.
[0131] In some embodiments, the present invention is directed to an antibody formulation comprising an antibody or antigen-binding fragment thereof, wherein the antibody is anifrolumab, and the antibody formulation is essentially free of particles. In some embodiments, the term "essentially free of particles" refers to the absence of visible particles when viewed under a light box. In some embodiments, the term "essentially free of particles" is synonymous with the phrase "low to undetectable levels of particle formation" above. In some embodiments, essentially free of particles refers to a sample containing less than 30 particles / mL, less than 20 particles / ml, less than 20 particles / ml, less than 15 particles / ml, less than 10 particles / ml, less than 5 particles / ml, less than 2 particles / ml, or less than 1 particle / ml, wherein the particles are greater than 25 μm, and the particle count is confirmed by HIAC analysis or visual analysis. In some embodiments, essentially free of particles refers to a sample containing 1-50 particles / mL, 2-40 particles / ml, 3-30 particles / ml, 4-25 particles / ml, or 5-20 particles / ml, where the particles are greater than 25 μm and the particle count is ascertained by HIAC analysis or visual analysis. In some embodiments, the term "visible particles" refers to particles greater than 25 μm.
[0132] In some embodiments, essentially free of particles refers to a sample containing 1-200 particles / mL, 10-150 particles / ml, about 30 particles / ml to 100 particles / ml, or 40-80 particles / ml, where the particles are larger than 5 μm and the particle count is confirmed by HIAC analysis or visual analysis. In some embodiments, the term "visible particles" refers to particles larger than 5 μm. In some embodiments, no particles are detected in the antibody formulation by either HIAC analysis or visual analysis.
[0133] In some embodiments, the invention is directed to an antibody formulation comprising an antibody or antigen-binding fragment thereof, wherein the antibody formulation is essentially free of particles for at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 8 months, at least 10 months, at least 12 months, or at least 18 months when stored at 38° C.-42° C., and the antibody is anifrolumab. In some embodiments, the invention is directed to an antibody formulation comprising an antibody or antigen-binding fragment thereof, wherein the antibody formulation is essentially free of particles for at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 8 months, at least 10 months, at least 12 months, at least 18 months, at least 24 months, at least 30 months, at least 36 months, or at least 48 months when stored at 2-6° C., and the antibody is anifrolumab.
[0134] In some embodiments, the present invention is directed to a method of purifying an antibody or antigen-binding fragment thereof, wherein the antibody is anifrolumab, comprising the steps of: (i) obtaining a cell culture comprising the antibody; (ii) subjecting the antibody to affinity chromatography; (iv) subjecting the antibody to cation exchange; and (v) subjecting the antibody to mixed-mode chromatography.
[0135] In some embodiments, the present invention is directed to a method for purifying an antibody or antigen-binding fragment thereof, wherein the antibody is anifrolumab, the method comprising the steps of (i) obtaining a cell culture comprising the antibody, (ii) binding the antibody to a Protein A column, (iii) eluting the antibody from the Protein A column, (iv) subjecting the antibody to cation exchange, and (v) subjecting the antibody to mixed-mode chromatography. In some embodiments, the method for purifying the antibody further comprises a viral inactivation treatment. In some embodiments, the viral inactivation step is performed by lowering the pH to less than 4.0. In some embodiments, the method further comprises a diafiltration treatment. In some embodiments, the method further comprises a filtration treatment. In some embodiments, the filtration treatment is sufficient to remove active viral particles.
[0136] In some embodiments, the present invention is directed to a method of treating a patient. In some embodiments, the method comprises administering to a subject in need thereof an antibody formulation as described herein, a container as described herein, a unit dose form as described herein, or a pre-filled syringe as described herein.
[0137] In some embodiments, the invention is suitable for treating a pulmonary disease or disorder by administering an antibody formulation described herein. In some embodiments, the invention is directed to a method of treating a patient with an eosinophilic disease or disorder by administering an antibody formulation described herein. In some embodiments, the invention is directed to a method of treating a pulmonary disease or disorder in a subject comprising administering an antibody formulation described herein. In some embodiments, the invention is directed to a method of treating an eosinophilic disease or disorder in a subject comprising administering an antibody formulation described herein. In some embodiments, the invention is directed to a method of treating a pulmonary disease or disorder, such as, for example, asthma, COPD, eosinophilic asthma, mixed eosinophilic-neutrophilic asthma, aspirin-sensitive asthma, allergic bronchopulmonary aspergillosis, acute and chronic eosinophilic bronchitis, acute and chronic eosinophilic pneumonia, Churg-Strauss syndrome, hypereosinophilic syndrome, drug-, irritant-, or radiation-induced pulmonary eosinophilia, infection-induced pulmonary eosinophilia (fungal, tuberculous, parasitic), autoimmune-related pulmonary eosinophilia, eosinophilic esophagitis, or Crohn's disease or a combination thereof, in a subject comprising administering an antibody formulation described herein. In some embodiments, the invention is directed to a method of treating asthma in a subject comprising administering an antibody formulation described herein. In some embodiments, the invention is directed to a method of treating COP in a subject comprising administering an antibody formulation described herein.
[0138] In some embodiments, a therapeutically effective amount of the antibody formulation described herein is administered to treat a disease state. As used herein, the term "therapeutically effective amount" refers to an amount of a therapy (e.g., an antibody that immunospecifically binds to an IFNAR1 polypeptide) sufficient to reduce the severity of a disease or disorder (e.g., a disease or disorder characterized by abnormal expression and / or activity of an IFNAR1 receptor polypeptide, a disease or disorder characterized by abnormal expression and / or activity of an IFNAR1 receptor or one or more subunits thereof, an autoimmune disease, an inflammatory disease, a proliferative disease, or an infectious disease or one or more symptoms thereof), reduce the duration of a disease state, improve one or more symptoms of such a disease or disorder, prevent the progression of such a disease or disorder, cause the regression of such a disease or disorder, or enhance or improve the therapeutic effect of another therapy. In some embodiments, a therapeutically effective amount may not be specified in advance and may be determined by a caregiver, such as, for example, a physician or other health care provider, using various means, such as, for example, dose escalation. An appropriate therapeutically effective amount may also be determined by routine experimentation, for example, using an animal model.
[0139] The terms "therapies" and "therapy" may refer to any protocol, method, and / or agent that may be used in the prevention, treatment, management, or amelioration of a disease or disorder (e.g., a disease or disorder characterized by aberrant expression and / or activity of an IFNAR1 polypeptide, a disease or disorder characterized by aberrant expression and / or activity of an IFNAR1 receptor or one or more subunits thereof, an autoimmune disease, an inflammatory disease, a proliferative disease, or an infectious disease (preferably a respiratory infection), or one or more symptoms thereof). In certain embodiments, the terms "therapy" and "therapy" refer to biological, supportive, and / or other therapeutic approaches known to a skilled medical practitioner that are useful in the treatment, management, prevention, or amelioration of such a disease or disorder or one or more symptoms.
[0140] As used herein, the term "therapeutic protocol" refers to a regimen for the dosing and timing of administration of one or more therapeutically effective therapies (eg, therapeutic agents).
[0141] The route of administration of the antibody formulation of the present invention may be, for example, via oral, parenteral, inhalation or topical administration. The term parenteral, as used herein, includes, for example, intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, rectal or vaginal administration. In some embodiments, the antibody is an anti-IFNAR1 antibody and the route of administration is intramuscular injection. While all of these modes of administration are expressly contemplated within the scope of the present invention, in some embodiments, the antibody formulation is suitable for administration by injection, particularly intravenous or intraarterial injection or infusion.
[0142] In some embodiments, the compositions and methods of the invention enable manufacturers to produce antibody formulations suitable for human administration in a more efficient manner, either by reducing costs, reducing process steps, reducing the opportunity for error, reducing the opportunity for introduction of unsafe or inappropriate additives, reducing waste, increasing storage time, etc. EXAMPLES
[0143] The invention will now be described with reference to the following examples, which are for illustrative purposes only, and the invention is not in any way limited to these examples, but rather should be construed to encompass any and all variations that become evident as a result of the teachings provided herein.
[0144] Example 1 material and method material All materials used were USP or multi-complementary grade. All solutions and buffers were prepared using USP or HPLC water and filtered before further use. Samples for stability testing were prepared under sterile conditions in a biosafety cabinet hood (BSC). Bulk materials were stored at 2-8 °C. Stability testing was performed with the supplies listed in Table 3. [Table 3]
[0145] Protein concentration determination Protein concentration was determined by measuring absorbance at 280 nm with an Agilent UV-Vis spectrophotometer using a method adapted from SOPDV-6233. A measured extinction coefficient of 1.39 (mg / mL)-cm was used. For samples, density correction factors for sugar or non-sugar containing formulations according to TD-0025 were applied.
[0146] Cone and plate viscosity measurements Viscosity was measured using an Anton Paar MCR301 rheometer equipped with a cone and plate attachment. To minimize the volume required, a 20 mm cone was used with one replicate measurement for screening purposes. Results are reported at the high shear limit of 1000 shear rates per second.
[0147] Purity determination by size exclusion chromatography (HPSEC) SEC was performed on an Agilent HPLC instrument with a TSK-Gel G3000 according to current formulation science guidelines.
[0148] exterior Visual inspection of the samples was performed by examining them in their respective containers for color and clarity using particle standards and indicators adapted from Standard Operating Procedures: Visual Appearance Evaluation of Protein Drug Substance and Drug Product.
[0149] Studies to evaluate the effect of excipient levels on stability and viscosity A design of experiment approach was utilized to study the effect of concentration, trehalose level, and lysine HCl level (factors) on stability and viscosity (response). A Box-Behnken design was created using JMP 9.1 software (SAS, Inc., Cary, NC). The design included the factors concentration (100-200 mg / mL); trehalose level (0-211 mM); and lysine HCl level (25-130 mM). pH was set at 6.0 based on previous formulation stability data for the cycle 1 formulation. Polysorbate level was set at 0.02%. At higher concentrations, a low lysine level was defined as 25 mM based on a preliminary high-throughput viscosity screening study where a significant decrease in viscosity was observed over the range of 0-25 mM lysine HCL (see Example 2). Stability was assessed by performing accelerated stability studies at 40°C with appearance and purity assessment by HP-SEC (monomer loss, aggregation, fragmentation). Subvisible particle counts after 1.8 months at 5°C were also measured, but no significant differences were observed between samples and therefore were not analysed further.
[0150] Effect of firmness and lysine HCl concentration on viscosity profile A stock solution of MEDI-546 at approximately 200 mg / mL in 25 mM histidine / histidine HCl, 25 mM lysine HCl (note: this is in the low lysine HCl category), 130 mM trehalose dihydrate (pH 6.0) was prepared and a dilution series was prepared incorporating 0.02% polysorbate 80. Concentrations and viscosities were measured and plotted. The nominal formulation condition (50 mM lysine HCl) was also prepared and measured. A 0.5 M lysine HCl stock solution was prepared and used to spike the MEDI-546 stock solution to the nominal 50 mM lysine level. Identical dilutions and formulations were performed to measure viscosity and concentration.
[0151] Functional evaluation of lead formulations in 27Ga STW prefilled syringes A prefilled syringe ("PFS") (BD Hypak SCF 1MLL 27G1 / 2-SB; 0.4 mg silicone oil MDN, fitted with a 27GSTW thin wall needle) was filled with 150 mg / mL MEDI-546 in 25 mM histidine / histidine HCl, 50 mM lysine HCl, 130 mM trehalose dihydrate, 0.05% polysorbate 80, pH 5.9. The viscosity of this lot was measured to be 9.4 mPas and the concentration was 150.7 mg / mL. A BD Hypak SCF 1MLL 4023 FLUR Daikyo SI1000 stopper was fitted with a vacuum stopper. Glide performance was measured at 260 mm / min using an Instron 5542 (Norwood, MA 02062). In addition, three analysts assessed latency to injection with and without arthritis simulation gloves (arthritis gloves from Georgia Tech Research Institute and injection trainer from Limbsnthings, UK).
[0152] Example 2 Summary of high-throughput viscosity screening results High-throughput viscosity screening was performed using nanoparticles. Briefly, nanoparticles of known size were measured in water (known viscosity) and in a sample (unknown viscosity), and the ratio was used to determine the viscosity of the unknown sample. These data were collected for screening and trending purposes, not for absolute viscosity measurements.
[0153] The HTS screening results of viscosity against pH are shown in Figure 1. The results suggested that the viscosity increased with pH. Based on this potential pH effect on viscosity and the possible domain type effect in TFF, the inventors determined that the formulation pH should be selected at 5.9. For the development of PFS, further robustness centered on the effect of pH is required. The HTS screening results of viscosity against lysine HCl (Figure 2) showed a significant decrease in viscosity over 0 - 25 mM lysine HCl. Practical laboratory observations of sample preparation also showed that the sample viscosity was higher without lysine and handling at higher concentrations was difficult. For this reason, the experiment started with 25 mM lysine HCl at a low level.
[0154] Example 3 Comprehensive Evaluation of Formulation Stability and Viscosity Table 4 shows an overview of the viscosity and accelerated stability results of the antibody formulations. Table 5 shows an overview of the results of subvisible particles (by HIAC) of the formulations after 1.8 months at 5°C. The comprehensive evaluation of the results showed that the purity degradation rates at 40°C were all acceptable, in the range of 3.8 - 4.8% per month. The fragmentation rate was in the range of 2.8 - 3.4% per month, and the aggregation rate was in the range of 0.7 - 2.0% per month. Visual inspection after 1 month at 40°C showed similar performance for all formulations (all particles were standard 1, transparency was <III or II, color was Y6). The subvisible particle (HIAC) data showed that all samples had less than 670 particles larger than 10 microns per mL. The viscosity was in the range of 2.8 - 39.7 mPas for all formulations. Some of the 150 mg / mL formulations had acceptable viscosity values.
[0155] Additional analysis of the data in the following examples shows how the data was used and interpreted to select a suitable and robust formulation that provides an acceptable viscosity while maximizing stability. [Table 4] [Table 5]
[0156] Example 4 Analyzing the results Table 6 summarizes the interpretations and conclusions drawn from the data. [Table 6]
[0157] Based on the analytical results, a formulation having 150 mg / mL MEDI-546 in 25 mM histidine / histidine HCl, 50 mM lysine HCl, 130 mM trehalose dehydrate, 0.05% polysorbate 80, pH 5.9 was further evaluated.
[0158] Example 6 Confirmation of antibody formulation viscosity and syringe functionality Ideally, the slippage force of a prefilled syringe should be as low as possible to ensure functionality. In this study, we target a viscosity of less than 20 mPas and a slippage force of less than 15 N. Previous experience has shown that formulations with nominal viscosities of less than 15 mPas have acceptable slippage performance when fitted with a 27-gauge thin-walled needle. With a 27Ga STW PFS, a maximum of 20 mPas may be achievable. The formulation and PFS should include firmness to compensate for syringe and formulation variability.
[0159] In this section, we present additional data demonstrating the robustness of the formulation viscosity versus concentration curve when compared to the lower end (25 mM) Lysine HCl formulation. The slip performance and injection time feasibility results of the nominal formulations in the 27Ga STW PFS are also evaluated in this section.
[0160] Effect of firmness and lysine HCl concentration on viscosity profile A dilution series of MEDI-546 spanning 100-200 mg / mL was prepared in two formulations. They contained MEDI-546 in 25 mM histidine / histidine-HCl, 130 mM trehalose dehydrate, 0.02% polysorbate 80 (pH 6.0) with either 25 mM or 50 mM lysine HCl. Viscosity curves are shown in Figure 3. Results indicate that the viscosity of formulations with both low (25 mM) and nominal (50 mM) lysine levels is acceptable at 150 mg / mL (<15 mPas), both below approximately 20 mPas at 165 mg / mL. Thus, the results confirm that the nominal level of 50 mM lysine HCl adequately separates from the low level of 25 mM in terms of viscosity performance. Based on the effect of pH on viscosity and possible Doman-type effects during TFF, the pH of the antibody formulation was selected to be 5.9.
[0161] Evaluation of the functionality of antibody formulations in prefilled syringes Table 7 shows the results of functional evaluation of a formulation having 150 mg / mL MEDI-546 in 25 mM histidine / histidine HCl, 50 mM lysine HCl, 130 mM trehalose dehydrate, 0.05% polysorbate 80, pH 5.9.
[0162] The force required to inject the MEDI-546 drug product was within acceptable limits. Table 8 shows the results of the user injection evaluation (laboratory analyst). Users reported that "the injection force was light," "the arthritic gloves made the APFS difficult to handle," and "the SSI device worked." There was some variability in the injection speed due to users' first use of the injection trainer and gloves (Note: the force to inject was not an issue). These results indicate that this formulation is suitable for use in a PFS fitted with a 27Ga STW needle. These studies did not identify any issues with the viscosity of the antibody formulation. [Table 7] [Table 8]
[0163] Example 7 Effect of lysine and protein on viscosity The viscosity of lysine solutions at different concentrations was measured as a function of protein (anifrolumab) concentration, as shown in Table 9 and FIG. 4. [Table 9]
[0164] The viscosity of antibody (anifrolumab) solutions at different concentrations was measured as a function of protein concentration, as shown in Table 10 and FIG. 5. [Table 10]
[0165] The examples given above illustrate various aspects of the present invention and the implementation of the method of the present invention. These examples are not intended to provide an exhaustive description of many different embodiments of the present invention. Therefore, although the present invention has been described in some detail by examples and examples for clarity of understanding, those skilled in the art will easily understand that many changes and modifications can be made without departing from the spirit or scope of the appended claims.
[0166] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference herein.
Claims
1. a. about 150-200 mg / mL anifrolumab; b. about 25-150 mM lysine salt; c. uncharged excipients; A stable antibody formulation comprising:
2. 2. The antibody formulation of claim 1, wherein the formulation is at a pH of 5.5 to 6.25, optionally at a pH of 5.
9.
3. 3. The antibody formulation of claim 1 or 2, wherein the lysine salt is selected from the group consisting of lysine acetate, lysine monochloride, lysine dichloride, lysine L-aspartate, lysine L-glutamate and lysine HCl.
4. The antibody formulation of any one of claims 1 to 3, further comprising a surfactant.
5. The antibody formulation of any one of claims 1 to 4, wherein the surfactant is selected from the group consisting of Triton X-100, Tween 80, polysorbate 20, polysorbate 80, nonoxynol-9, poloxamer, stearyl alcohol, sodium dodecyl sulfate, and sorbitan monostearate.
6. The antibody formulation of claim 5 , wherein the surfactant is polysorbate 80.
7. The antibody formulation of any one of claims 1 to 6, comprising about 0.02% to about 0.08% of a surfactant.
8. The antibody formulation of any one of claims 1 to 7, comprising about 0.05% of a surfactant.
9. The antibody formulation of any one of claims 1 to 8, comprising a formulation buffer.
10. 10. The antibody formulation of claim 9, wherein the formulation buffer is acetate buffer, Tris buffer, HEPES buffer, hydrochloric acid buffer, arginine buffer, glycine buffer, citrate buffer, histidine buffer, or TES buffer.
11. 10. The antibody formulation of claim 9, wherein the formulation buffer is a histidine buffer.
12. The antibody formulation of claim 11 , wherein the histidine buffer comprises histidine hydrochloride.
13. The antibody formulation of claim 11 , wherein the formulation buffer is histidine / histidine hydrochloride.
14. The antibody formulation of claim 12, wherein the buffer comprises about 10 mM to about 40 mM histidine / histidine hydrochloride.
15. The antibody formulation of claim 13, wherein the buffer comprises about 25 mM histidine / histidine hydrochloride.
16. 16. The antibody formulation of any one of claims 1 to 15, wherein the uncharged excipient is selected from the group consisting of fructose, glucose, mannose, sorbose, xylose, lactose, maltose, sucrose, dextran, pullulan, dextrin, cyclodextrin, soluble starch, trehalose, sorbitol, erythritol, isomalt, lactitol, maltitol, xylitol, glycerol, hydroxyethyl starch, and water soluble glucan.
17. 17. The antibody formulation of claim 16, wherein the uncharged excipient is selected from the group consisting of glucose, sucrose, trehalose, and glycerol.
18. The antibody formulation of any one of claims 1 to 17, wherein the uncharged excipient is trehalose.
19. 19. The antibody formulation of claim 18, wherein the uncharged excipient is trehalose dihydrate.
20. The antibody formulation of any one of claims 1 to 19, comprising about 100 mM to about 150 mM of an uncharged excipient.
21. The antibody formulation of any one of claims 1 to 20, suitable for intravenous, subcutaneous, or intramuscular administration.
22. A pre-filled syringe comprising the antibody formulation of any one of claims 1 to 21.
23. 22. A pharmaceutical composition comprising the antibody formulation of any one of claims 1 to 21 for use in a method of treating a type I IFN-mediated disease or disorder in a subject in need thereof, the method comprising administering a therapeutically effective amount of the antibody formulation.
24. 24. The pharmaceutical composition of claim 23, wherein the disease or disorder is selected from the group consisting of systemic lupus erythematosus (SLE), insulin-dependent diabetes mellitus, inflammatory bowel disease, multiple sclerosis, psoriasis, autoimmune thyroiditis, rheumatoid arthritis, glomerulonephritis, scleroderma, myositis, and lupus nephritis.
25. 25. The pharmaceutical composition of claim 24, wherein the disease or disorder is systemic lupus erythematosus.
Citation Information
Patent Citations
Production of gamma-globulin for intravenous injection
JP1982031623A
Composition of a specific binder for hepatocyte growth factor
JP2010531306A
Anti-IFNAR1 antibodies with reduced Fc ligand affinity
JP2011514150A
Pharmaceutical preparations
JP2015509526A
